Literature DB >> 17485151

Prophylactic DNA immunization against multiple papillomavirus types.

Maja Gasparić1, Ivonne Rubio, Nadja Thönes, Lutz Gissmann, Martin Müller.   

Abstract

At least 15 different papillomavirus types are causatively associated with the development of tumors in humans. Since the middle of 2006 a protective, virus-like particle based vaccine against the tumor-related HPV types 16 and 18 is commercially available. We investigated the possibility of applying DNA vaccination to obtain protective antibody responses against multiple papillomavirus types. Our data indicate that low amounts of DNA were sufficient to induce neutralizing antibodies in mice although a DNA dose-dependency in respect to the L1-specific antibody titers was observed. Furthermore, we found that immune responses against different PV types could be induced by simultaneous DNA vaccination with a mixture of expression vectors encoding L1 proteins of different papillomavirus types. However, we observed that there was a strong interference when plasmids encoding different L1 genes were used together. HPV 16 responses were repressed by co-administration of HPV 11 and/or BPV 1 L1 expression constructs. Likewise, BPV 1 responses were repressed by co-administration of HPV 16 or HPV 11 L1 plasmids. This interference could be overcome by administration of the different constructs into different sites of the animals or by sequential immunization. Thus, our results suggest that the mode of repression was due to interference with L1 particle assembly and was not a consequence of immunodominance of certain L1 proteins.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17485151     DOI: 10.1016/j.vaccine.2007.04.001

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  7 in total

1.  A multi-head intradermal electroporation device allows for tailored and increased dose DNA vaccine delivery to the skin.

Authors:  Jay R McCoy; Janess M Mendoza; Kristin W Spik; Catherine Badger; Alan F Gomez; Connie S Schmaljohn; Niranjan Y Sardesai; Kate E Broderick
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response.

Authors:  Nadja Thönes; Anna Herreiner; Lysann Schädlich; Konrad Piuko; Martin Müller
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

3.  Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies.

Authors:  Nicolas Combelas; Emilie Saussereau; Maxime J J Fleury; Tatiana Ribeiro; Julien Gaitan; Diego F Duarte-Forero; Pierre Coursaget; Antoine Touzé
Journal:  J Transl Med       Date:  2010-03-24       Impact factor: 5.531

4.  The future of vaccines for cervical cancer.

Authors:  Warner K Huh; Richard B S Roden
Journal:  Gynecol Oncol       Date:  2008-05       Impact factor: 5.482

5.  Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation.

Authors:  Kihyuck Kwak; Rosie Jiang; Subhashini Jagu; Joshua W Wang; Chenguang Wang; Neil D Christensen; Richard B S Roden
Journal:  PLoS One       Date:  2013-03-25       Impact factor: 3.240

6.  Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques.

Authors:  Christiane Stahl-Hennig; Martin Eisenblätter; Edith Jasny; Tamara Rzehak; Klara Tenner-Racz; Christine Trumpfheller; Andres M Salazar; Klaus Uberla; Karen Nieto; Jürgen Kleinschmidt; Reiner Schulte; Lutz Gissmann; Martin Müller; Anna Sacher; Paul Racz; Ralph M Steinman; Mariagrazia Uguccioni; Ralf Ignatius
Journal:  PLoS Pathog       Date:  2009-04-10       Impact factor: 6.823

7.  A multi-head intradermal electroporation device allows for tailored and increased dose DNA vaccine delivery to the skin.

Authors:  Jay R McCoy; Janess M Mendoza; Kristin W Spik; Catherine Badger; Alan F Gomez; Connie S Schmaljohn; Niranjan Y Sardesai; Kate E Broderick
Journal:  Hum Vaccin Immunother       Date:  2014-11-21       Impact factor: 3.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.